{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T23:41:27Z","timestamp":1701906087887},"reference-count":57,"publisher":"Informa UK Limited","issue":"12","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2016,12,1]]},"DOI":"10.1080\/13543776.2016.1227321","type":"journal-article","created":{"date-parts":[[2016,8,30]],"date-time":"2016-08-30T09:48:54Z","timestamp":1472550534000},"page":"1449-1457","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Case study of patents related to captopril, Squibb\u2019s first blockbuster"],"prefix":"10.1080","volume":"26","author":[{"given":"Adelaide Maria de Souza","family":"Antunes","sequence":"first","affiliation":[{"name":"Postgraduate Program in Technology of Chemical & Biochemical Processes, Federal University of Rio de Janeiro (UFRJ)\/National Institute of Industrial Property, Academy of Innovation and Intellectual Property (INPI-Brazil), Rio de Janeiro, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafaela Di Sabato","family":"Guerrante","sequence":"additional","affiliation":[{"name":"National Institute of Industrial Property, Academy of Innovation and Intellectual Property, General Coordination of International Affairs (INPI-Brazil), Rio de Janeiro, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge de Paula Costa","family":"\u00c1vila","sequence":"additional","affiliation":[{"name":"Federal University of the State of Rio de Janeiro, Public Administration School (UNIRIO), Rio de Janeiro, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flavia Maria","family":"Lins Mendes","sequence":"additional","affiliation":[{"name":"School of Chemistry (SIQUIM), Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iolanda M.","family":"Fierro","sequence":"additional","affiliation":[{"name":"National Institute of Industrial Property, Academy of Innovation and Intellectual Property, General Coordination of International Affairs (INPI-Brazil), Rio de Janeiro, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2016,9,1]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-139-9-200311040-00011"},{"key":"CIT0002","unstructured":"World Health Organization. The top 10 causes of death; 2012. [cited 2016 Jul 25]. Available from: http:\/\/www.who.int\/mediacentre\/factsheets\/fs310\/en\/."},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1016\/j.jash.2010.02.005"},{"issue":"3","key":"CIT0004","first-page":"160","volume":"2","author":"Aronow WS","year":"2012","journal-title":"Am J Cardiovasc Dis"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1177\/1753944715578056"},{"key":"CIT0006","unstructured":"Top 20 Global Therapy Areas 2014. IMS Health Intelligence Applied. London, UK: IMS Health HQ Limited; 2014. [cited 2016 Apr 18]. Available from: https:\/\/www.imshealth.com\/files\/web\/Corporate\/News\/Top-Line%20Market%20Data\/2014\/Top_20_Global_Therapy_Classes_2014.pdf."},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1002\/tera.1420500606"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000090572.51900.92"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1038\/13423"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1096\/fj.06-0602ufm"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1021\/bi00815a005"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(71)91005-1"},{"key":"CIT0013","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0021-9258(19)45746-3","volume":"247","author":"Byers LD","year":"1972","journal-title":"J Biol Chem"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1021\/bi00644a014"},{"key":"CIT0015","volume-title":"Patents. intellectual property primer course","author":"World Intellectual Property Organization","year":"2014"},{"key":"CIT0016","unstructured":"Neugebauer J, ER SQUIBB & SONS INC. Azetidine-2-carboxylic acid derivatives. US4046889. 1977."},{"key":"CIT0017","unstructured":"ER SQUIBB & SONS INC. Pyroglutamic acid derivatives and analogs. US4234489. 1980."},{"key":"CIT0018","unstructured":"ER SQUIBB & SONS INC. Mercaptoacyldihydropyrazole carboxylic acid derivatives. US4266065. 1981."},{"key":"CIT0019","unstructured":"ER SQUIBB & SONS INC. Mercaptoacyl derivatives of 4-oxazolidine-carboxylic acids. US4321392. 1982."},{"key":"CIT0020","unstructured":"ER SQUIBB & SONS INC. S-Acylation products of mercaptoacyl amino acids and carboxyl group containing diuretics. US4482725. 1984."},{"key":"CIT0021","unstructured":"ER SQUIBB & SONS INC. Substituted 4-phenoxy or 4-phenylthio pralines. US4536501. 1985."},{"key":"CIT0022","unstructured":"BRISTOL MYERS SQUIBB CO. Diazepine containing dual action inhibitors. US5646276. 1997."},{"key":"CIT0023","unstructured":"BRISTOL MYERS SQUIBB CO. Compounds containing a fused bicycle ring and processes therefor. US5508272. 1996."},{"key":"CIT0024","unstructured":"Romagnolo D, Polan CE, Barbeau WE, BRISTOL MYERS SQUIBB. Substituted azepino[2,1-a]isoquinoline compounds. US5362727. 1994."},{"key":"CIT0025","unstructured":"BRISTOL MYERS SQUIBB CO. Azepinone compounds useful in the inhibition of ACE and NEP. US5587375. 1996."},{"key":"CIT0026","unstructured":"Chadwick BP, Campbell LJ, Jackson CL, et al. BRISTOL MYERS SQUIBB. Benzo-fused azepinone and piperidinone compounds useful in the inhibition of ACE and NEP. US5877313. 1999."},{"key":"CIT0027","unstructured":"BRISTOL MYERS SQUIBB CO. Diazepine containing dual action inhibitors. US5635504. 1997."},{"key":"CIT0028","unstructured":"BRISTOL MYERS SQUIBB CO. Thiazolo benzazepine containing dual action inhibitors. EP747393. 1996."},{"key":"CIT0029","unstructured":"ER SQUIBB & SONS INC. Substituted azepinone dual inhibitors of angiotensin converting enzyme and neutral exdopeptidase. US5552397. 1996."},{"key":"CIT0030","unstructured":"BRISTOL MYERS SQUIBB CO. Benzo-fused lactams. US5504080. 1996."},{"issue":"11","key":"CIT0031","first-page":"1305","volume":"25","author":"Kellici TF","year":"2015","journal-title":"Expert Opin Ther Pat"},{"key":"CIT0032","unstructured":"BRISTOL MYERS SQUIBB CO. Angiotensin converting enzyme (ace) inhibitors containing a fused multiple ring lactam. EP657453. 1995."},{"key":"CIT0033","unstructured":"ER SQUIBB & SONS INC. Phosphinylalkanoyl substituted 4,5-dihydropyrazole-5-carboxylic acid derivatives and hypotensive method and composition. US4371526. 1983."},{"key":"CIT0034","unstructured":"BRISTOL MYERS SQUIBB CO. Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein. WO2003043624. 2003."},{"key":"CIT0035","unstructured":"ER SQUIBB & SONS INC. Reaction products of pyrazolo[1,5-c]quinazoline derivatives and proline derivatives and methods for reducing blood pressure while inhibiting allergic reactions with them. US4307099. 1981."},{"key":"CIT0036","unstructured":"ER SQUIBB & SONS INC. Phosphonate substituted amino acids useful as antihypertensives. US5102875. 1992."},{"key":"CIT0037","unstructured":"ER SQUIBB & SONS INC. Derivatives of mercaptoacyl amino acids. GB2050359. 1981."},{"key":"CIT0038","unstructured":"ER SQUIBB & SONS INC. Acylalkylaminocarbonyl substituted amino and imino acid compounds. EP103496. 1984."},{"key":"CIT0039","unstructured":"BRISTOL MYERS SQUIBB CO. Process for preparing homocystein analogs useful as intermediates for compounds containing a fused bicyclic ring. US5616775. 1997."},{"key":"CIT0040","unstructured":"Miyoshi T, Hanazawa S, Hirose K, et al. ER SQUIBB & SONS INC. Process and intermediates for preparing trans-4-substituted-s-prolines. US4588819. 1986."},{"key":"CIT0041","unstructured":"ER SQUIBB & SONS INC. Purification of mercaptoacyl amino acids. US4332726. 1982."},{"key":"CIT0042","unstructured":"ER SQUIBB & SONS INC. Inhibitors of mammalian collagenase. US4235885. 1980."},{"key":"CIT0043","unstructured":"ER SQUIBB & SONS INC. Heterocyclic containing amides as inhibitors of mammalian collagenase. US4263293. 1980."},{"key":"CIT0044","unstructured":"Verdi RJ, Barbano DM, ER SQUIBB & SONS INC. Enkephalinase inhibitors. US4722810. 1988."},{"key":"CIT0045","unstructured":"BRISTOL MYERS SQUIBB CO. Sustained release formulation containing captopril and method. US5433951. 1995."},{"key":"CIT0046","unstructured":"ER SQUIBB & SONS INC. Captopril formulation providing increased duration of activity. US5158777. 1992."},{"key":"CIT0047","unstructured":"Verdi RJ, Barbano DM, ER SQUIBB & SONS INC. Controlled release formulation and method. US4738850. 1988."},{"key":"CIT0048","unstructured":"ER SQUIBB & SONS INC. Hydroxy substituted peptide compounds. US4514391. 1985."},{"key":"CIT0049","unstructured":"ER SQUIBB & SONS INC. Phosphonamidate compounds. US4432972. 1984."},{"key":"CIT0050","unstructured":"BRISTOL-MYERS SQUIBB CMPANY. HMG-CoA reductase inhibitors and method. US7371759. 2005."},{"key":"CIT0051","unstructured":"BRISTOL-MYERS SQUIBB COMPANY. HMG-CoA reductase inhibitors and method. US7420059. 2005."},{"key":"CIT0052","unstructured":"RESET THERAPEUTICS INC. Carbazole-containing sulfonamides as cryptochrome modulators. WO2013170186. 2013."},{"key":"CIT0053","unstructured":"WOCKHARDT LIMITED. Methods for treating cardiovascular disorders. WO2013030725. 2013."},{"key":"CIT0054","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0b013e328356c551"},{"key":"CIT0055","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2010.534129"},{"key":"CIT0056","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2014.05.002"},{"key":"CIT0057","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.10.027"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2016.1227321","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T10:09:37Z","timestamp":1657188577000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2016.1227321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,1]]},"references-count":57,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12,1]]}},"alternative-id":["10.1080\/13543776.2016.1227321"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2016.1227321","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,1]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2016-05-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-08-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-09-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}